In a more recent study to investigate targeted therapy, Kortmann et al. established PDX models from a BRCA wild-type and a BRCA2 germline-mutated HG-SOC tumor to examine response to the PARP inhibitor, olaparib (46). The gene discussed is PARP1; the disease is neoplasm.